NasdaqCM - Nasdaq Real Time Price USD

Vistagen Therapeutics, Inc. (VTGN)

Compare
2.5000 +0.2500 (+11.11%)
At close: December 20 at 4:00:01 PM EST
2.6000 +0.10 (+4.00%)
After hours: December 20 at 7:43:02 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
876.0000
1,064.0000
-227.0000
1,108.9000
1,089.5000
Operating Expense
46,477.0000
34,085.0000
59,041.0000
48,655.8000
19,023.7000
Operating Income
-45,601.0000
-33,021.0000
-59,268.0000
-47,546.9000
-17,934.2000
Net Non Operating Interest Income Expense
5,732.0000
3,351.0000
26.0000
20.0000
2.0000
Other Income Expense
--
312.0000
--
-232.0000
0.6000
Pretax Income
-39,557.0000
-29,358.0000
-59,242.0000
-47,759.0000
-17,931.6000
Tax Provision
8.0000
4.0000
6.0000
3.4000
2.6000
Net Income Common Stockholders
-39,565.0000
-29,362.0000
-59,248.0000
-48,707.5000
-42,319.8000
Diluted NI Available to Com Stockholders
-39,565.0000
-29,362.0000
-59,248.0000
-48,707.5000
-42,319.8000
Basic EPS
-0.74
-1.52
-8.51
-7.38
-14.70
Diluted EPS
-0.74
-1.52
-8.51
-7.38
-14.70
Basic Average Shares
30,304.9600
19,354.5000
6,959.4440
6,599.9460
2,871.1210
Diluted Average Shares
30,304.9600
19,354.5000
6,959.4440
6,599.9460
2,871.1210
Total Operating Income as Reported
-45,601.0000
-33,021.0000
-59,268.0000
-47,778.9000
-17,933.8000
Rent Expense Supplemental
--
--
419.0000
377.0000
354.0000
Total Expenses
46,477.0000
34,085.0000
59,041.0000
48,655.8000
19,023.7000
Net Income from Continuing & Discontinued Operation
-39,565.0000
-29,362.0000
-59,248.0000
-47,762.4000
-17,934.2000
Normalized Income
-39,565.0000
-29,362.0000
-59,248.0000
-47,530.6784
-17,934.2000
Interest Income
--
--
49.0000
20.0000
15.0000
Interest Expense
--
--
23.0000
--
13.0000
Net Interest Income
5,732.0000
3,351.0000
26.0000
20.0000
2.0000
EBIT
-45,601.0000
-33,021.0000
-59,268.0000
-47,759.0000
-17,918.6000
EBITDA
-45,003.0000
-32,453.0000
-58,736.0000
-47,047.9000
-17,441.0000
Reconciled Depreciation
598.0000
568.0000
532.0000
711.1000
477.6000
Net Income from Continuing Operation Net Minority Interest
-39,565.0000
-29,362.0000
-59,248.0000
-47,762.4000
-17,934.2000
Total Unusual Items Excluding Goodwill
--
--
--
-232.0000
--
Total Unusual Items
--
--
--
-232.0000
--
Normalized EBITDA
-45,003.0000
-32,453.0000
-58,736.0000
-46,815.9000
-17,441.0000
Tax Rate for Calcs
0.0002
--
--
0.0000
--
Tax Effect of Unusual Items
--
--
--
-0.2784
--
3/31/2021 - 6/21/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TENX Tenax Therapeutics, Inc.
5.61
+2.56%
 
OTLK Outlook Therapeutics, Inc.
1.4400
+3.60%
 
VSTM Verastem, Inc.
4.1900
-5.63%
 
TPST Tempest Therapeutics, Inc.
0.7116
-1.17%
 
ALDX Aldeyra Therapeutics, Inc.
4.8800
+0.41%
 
SAGE Sage Therapeutics, Inc.
5.61
+12.20%
 
OVID Ovid Therapeutics Inc.
0.9991
-2.05%
 
VTVT vTv Therapeutics Inc.
14.96
+3.03%
 
TSVT 2seventy bio, Inc.
3.1400
+7.53%
 
XBIO Xenetic Biosciences, Inc.
4.2900
+4.63%